Article
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Cancer discovery - 2 May 2025
Sharifi Marina N, Sperger Jamie M, Taylor Amy K, Tippins Katharine E, Reese Shannon R, Carreno Viridiana, Kaufmann Katherine R, Chang Alex H, Nunamaker Luke A, Linebarger Charlotte, Mora-Rodriguez Leilani, Schehr Jennifer L, Krause Hannah M, Helzer Kyle T, Bootsma Matthew L, Blitzer Grace C, Floberg John M, Kyriakopoulos Christos E, Emamekhoo Hamid, Heath Elisabeth I, Wells Meghan, Tagawa Scott T, Sjöström Martin, Choudhury Atish D, Yu Menggang, Armstrong Andrew J, Rathkopf Dana E, Beltran Himisha, Nelson Peter S, Feng Felix Y, Dehm Scott M, Kosoff David, Wei Xiao X, McKay Rana R, Zhao Shuang G, Lang Joshua M
Abstract excerpt
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance has been limited by the challenges of collecting serial tissue biopsies on treatment, which can be overcome using blood-based liquid biopsies. Utilizing a novel circulating tumor cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.